L’AIFA effettua il monitoraggio mensile dei dati di spesa farmaceutica e comunica le relative risultanze al Ministero della salute ed al Ministero dell’economia e delle finanze con la medesima cadenza.
The document is divided into 7 sections:
2. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases net of medicinal gases (6.69% of the national health requirement) calculated on the final 2019 FSN.
3. Expenditure on Innovative drugs and verification of any excess expenditure with respect to the innovative non-oncological funds and the innovative oncological drug fund envisaged by Law 232 of 11 December 2016.
4. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases of medicinal gases (0.20% of the national health requirement) calculated on the final 2019 FSN.
5. Overall pharmaceutical expenditure January-December 2019 and verification of compliance with overall resources.
6. Source of data.
7. Appendix.
Table 3 Summary of net subsidized pharmaceutical expenditure in the period January-December 2019, in the individual regions, compared to the same period of 2018
There table 4a indicates, for each Region, a set of indicators of expenditure and per capita consumption of the approved pharmaceutical, considering the weighted population for the year 2019.
For other useful information, see the AIFA text
by clicking here: complete document
Note: to enlarge the tables click on them